Here's Why You Should Add INSP Stock to Your Portfolio Now
Inspire Medical Systems (INSP) is considered a strong buy due to its significant product transition and potential for growth in the underpenetrated obstructive sleep apnea (OSA) market. Despite a recent stock decline, the company is expanding its Inspire V system adoption, backed by strong clinical evidence and efforts to improve patient access. Challenges include reimbursement disruptions and potential pressure from GLP-1 therapies, but positive estimate revisions suggest a favorable outlook for 2026.
Inspire Medical Systems (NYSE:INSP) Stock Rating Upgraded by Zacks Research
Zacks Research has upgraded Inspire Medical Systems (NYSE:INSP) from a "hold" to a "strong-buy" rating. Despite this, the consensus among analysts remains "hold" with an average price target of $66.19. The company recently reported quarterly earnings of $0.14 per share, significantly exceeding estimates, and its revenue also surpassed expectations.
GSA Capital Partners LLP Purchases New Stake in Inspire Medical Systems, Inc. $INSP
GSA Capital Partners LLP recently acquired a new stake of 18,382 shares in Inspire Medical Systems, Inc. ($INSP) worth approximately $820,000, representing 0.06% of the company's stock. Institutional investors now collectively own 94.91% of Inspire Medical Systems. Analysts maintain a "Hold" rating with an average price target of $66.19, despite the company beating Q2 EPS estimates by reporting $0.14 per share against an expected $0.24 loss.
Inspire Medical Systems (INSP) Stock Trades Below Fair Value As Caution Lingers
Inspire Medical Systems (INSP) stock appears undervalued according to Discounted Cash Flow (DCF) and P/E ratio analyses, despite a significant 73.8% share price decline over three years. The DCF model suggests a 34.0% discount to intrinsic value, while its P/E ratio of 12.2x is well below industry averages and its estimated fair ratio. The article highlights contrasting narratives, with bull and bear cases discussing potential upside from product adoption versus risks from market erosion and product concentration.
Alberta Investment Management Corp Takes $5.48 Million Position in Inspire Medical Systems, Inc. $INSP
Alberta Investment Management Corp initiated a new position in Inspire Medical Systems (NYSE:INSP) during the second quarter, purchasing 122,900 shares valued at approximately $5.48 million. Institutional investors collectively hold 94.91% of the company's stock. Inspire Medical Systems recently reported stronger-than-expected quarterly earnings and revenue, though revenue was down 7.6% year-over-year, and analysts currently have a consensus "Hold" rating on the stock with a target price of $66.19.
Inspire Medical Systems (INSP) Updates Guidance As Valuation Questions Persist
Inspire Medical Systems (INSP) updated its full-year guidance and reported Q2 2026 results, leading to mixed stock performance with recent cooling despite a strong 90-day rebound. Analysts consider the stock 9.5% overvalued at $57.10 compared to a fair value of $52.17, citing potential reimbursement setbacks and slower product adoption as risks. However, its P/E ratio of 12.2x is significantly lower than the industry average, suggesting a potential undervaluation from a comparative perspective.
Which Medtech Giant Would Buy Inspire Medical Systems?
Inspire Medical Systems (INSP) is presented as an attractive takeover target due to its solid financials, strong balance sheet, and innovative neurostimulation technology for sleep apnea. The article identifies Medtronic, Boston Scientific, and Stryker as logical potential acquirers, estimating a deal value between $2.0 billion and $2.4 billion. It notes that INSP's dispersed ownership and lack of structural defenses make it an accessible target for a serious bidder.
Inspire Medical Systems (INSP): Soleus Capital group reports 6.7% ownership stake
Soleus Capital Master Fund, L.P. and affiliated entities have reported a 6.7% ownership stake in Inspire Medical Systems, Inc. (INSP), holding 1,931,436 shares of common stock. This beneficial ownership is based on 28,910,375 shares outstanding as of July 30, 2026, and grants shared voting and dispositive power over these shares. The disclosure was made via an amended Schedule 13G/A filing, indicating a passive investment intent.
AQR Capital discloses 6.44% Inspire Medical Systems (INSP) ownership on Schedule 13G
AQR Capital Management, LLC and its parent, AQR Capital Management Holdings, LLC, have disclosed a beneficial ownership of 6.44% in Inspire Medical Systems, Inc. (INSP) through a Schedule 13G filing. The AQR entities collectively own 1,856,800 shares, with shared voting power over 1,783,224 shares and shared dispositive power over all beneficially owned shares. This filing indicates AQR's significant passive investment in Inspire Medical Systems.
Inspire Medical Systems, Inc. (NYSE:INSP) Given Consensus Recommendation of "Hold" by Analysts
Analysts have issued a consensus "Hold" rating for Inspire Medical Systems, Inc. (NYSE:INSP), with an average 12-month price target of $68.00. The company recently reported quarterly EPS of $0.14, surpassing expectations, and revenue of $200.6 million, although revenue declined 7.6% year over year. Institutional investors hold a significant majority of shares at 94.91%, while insider ownership is 2.20%, with a recent insider sale of 963 shares.
Inspire medical systems chief mfg. officer Kelly sells $57,346 in stock
Jason P. Kelly, Chief Manufacturing and Quality Officer at Inspire Medical Systems (NASDAQ:INSP), sold 963 shares of company stock for a total of $57,346. Following the sale, Mr. Kelly directly owns 18,985 shares. Despite the stock being down 36% year-to-date, InvestingPro analysis suggests the company is undervalued and maintains profitability.
Inspire Medical Systems (NYSE:INSP) Insider Jason Kelly Sells 963 Shares of Stock
Inspire Medical Systems insider Jason Kelly sold 963 shares of the company's stock for approximately $57,346.65, reducing his holdings by 4.83%. The company recently reported better-than-expected quarterly earnings and revenue, but revenue was down 7.6% year-over-year. Analysts maintain a "Hold" rating on the stock with an average price target of $68.00.
Inspire Medical Systems (INSP) Q2 2026 Earnings Call Transcript
Inspire Medical Systems (INSP) reported Q2 2026 revenue of $200.6 million, a 7.6% decrease due to coding and reimbursement disruptions, but raised its full-year revenue guidance to $835 million to $875 million. The company launched "Project Horizon" to optimize its organizational structure and supply chain, aiming to free up $30 million for growth initiatives. Despite current challenges, Inspire is encouraged by proposed 2027 reimbursement rate increases and ongoing efforts to clarify coding for its Inspire V system.
Inspire Medical Systems (INSP) officer Jason P. Kelly sells 963 shares at $59.55
Jason P. Kelly, Chief Manufacturing and Quality Officer at Inspire Medical Systems (INSP), sold 963 shares of common stock at $59.55 per share on August 7, 2026. Following this transaction, Kelly directly holds 18,985 shares of the company. The sale was an open-market transaction and was not executed under a Rule 10b5-1 trading plan.
Price to sales ratio of Inspire Medical Systems, Inc. – HAM:2DR
This article focuses on the price to sales ratio of Inspire Medical Systems, Inc. (HAM:2DR) on the Hamburg Stock Exchange. It provides general financial overview information for the company as listed on TradingView.
Janus Henderson Group PLC Sells 548,880 Shares of Inspire Medical Systems, Inc. $INSP
Janus Henderson Group PLC significantly reduced its stake in Inspire Medical Systems, Inc. by selling 97.6% of its shares, retaining 13,451 shares valued at $694,000. Despite the sell-off, other institutional investors increased their positions in INSP. The company recently reported better-than-expected EPS but a year-over-year revenue decline, and analysts currently have a "Hold" consensus rating with an average price target of $68.
Inspire Medical Systems (INSP) Q2 2026 Earnings Call Transcript
Inspire Medical Systems reported Q2 2026 revenue of $200.6 million, a 7.6% decrease due to coding and reimbursement disruptions, but raised its full-year revenue guidance to $835 million to $875 million. The company launched "Project Horizon" to optimize its structure and supply chain, creating $30 million in annualized growth investment capacity, which will be directed towards enhancing patient flow and reinvigorating revenue growth in 2027 and beyond. Inspire is also focused on improving coding clarity, addressing reimbursement challenges, and leveraging clinical data, including new research on cardiovascular health benefits and reduced diagnostic burden with the Inspire V system.
5 Insightful Analyst Questions From Inspire Medical Systems’s Q2 Earnings Call
Inspire Medical Systems (INSP) surpassed Q2 analyst expectations with improved operating income and positive cash flow, driven by better coding clarity and cost discipline. Management raised its full-year revenue and Adjusted EPS guidance, demonstrating resilience despite a year-on-year revenue decline. Analyst questions focused on the impact of physician fee reductions, the timing of Project Horizon investments, procedure backlogs, the effect of GLP-1 drugs, and international growth, with management providing reassuring responses about ongoing recovery and strategic initiatives.
Inspire Medical Systems (INSP) Q2 2026 Earnings Call Transcript
Inspire Medical Systems (INSP) reported Q2 2026 earnings, with revenue decreasing 7.6% to $200.6 million due to coding and reimbursement disruptions. Despite challenges, the company raised its full-year revenue guidance and announced "Project Horizon," a strategic growth plan to optimize operations and invest $30 million in initiatives aimed at improving patient flow and accelerating growth. CMS proposed favorable 2027 facility reimbursement rate increases, and Inspire is working to secure a new Category 1 CPT code for its single lead system, while also leveraging clinical data highlighting cardiovascular benefits and simplified screening for its Inspire V therapy.
Inspire Medical Systems (INSP) Is Up 19.8% After Q2 Profit And Higher 2026 Guidance - Has The Bull Case Changed?
Inspire Medical Systems reported a swing to profit in Q2 2026 and raised its full-year 2026 revenue guidance, leading to a 19.8% stock increase. Despite this, the company faces ongoing challenges with the Inspire V rollout, marketing spend, and reimbursement policies. The article questions whether this recent profitability is sustainable given the previous, much higher analyst expectations and the current headwinds.
5 Insightful Analyst Questions From Inspire Medical Systems’s Q2 Earnings Call
Inspire Medical Systems outperformed Q2 expectations due to improved coding clarity and cost discipline, reporting higher revenue and adjusted EPS than anticipated. The company also slightly increased its full-year revenue and adjusted EPS guidance. Key analyst questions focused on the impact of physician fee reductions, Project Horizon's growth investments, procedure backlogs, the effect of GLP-1 drugs, and international growth.
Dimensional Fund Advisors LP Trims Holdings in Inspire Medical Systems, Inc. $INSP
Dimensional Fund Advisors LP reduced its stake in Inspire Medical Systems, Inc. (NYSE:INSP) by 31.3% in the first quarter, selling over 106,000 shares but retaining a significant holding valued at $12.1 million. Despite this trimming, institutional investors collectively own 94.91% of the company. Inspire Medical Systems beat earnings expectations for the quarter, reporting $0.14 per share against a projected $0.24 loss, though revenue declined year-over-year.
Class Action Lawsuit Filed Against Inspire Medical Systems, Inc
A securities class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) on behalf of investors who purchased securities between August 6, 2024, and August 4, 2025. The lawsuit alleges that Inspire Medical Systems made false statements and concealed critical issues regarding the disastrous launch of its new product, Inspire V. Investors who suffered losses are encouraged to contact Levi & Korsinsky, LLP before January 5, 2026, to explore potential recovery under federal securities laws.
Inspire Medical Systems, Inc. 2026 Q2 - Results - Earnings Call Presentation (NYSE:INSP) 2026-08-07
Inspire Medical Systems, Inc. (NYSE:INSP) has released its Q2 2026 earnings call presentation, detailing financial results that exceeded analyst expectations. The company reported an EPS of $0.14, beating estimates by $0.39, and revenue of $200.58M, surpassing expectations by $5.97M despite a 7.60% year-over-year decrease. The presentation provides further insights into these results for investors and stakeholders.
Inspire Medical Systems, Inc. SEC Filing (Aug 7, 2026)
This article reports on an SEC Form 144 filing by Inspire Medical Systems, Inc. (INSP) on August 7, 2026. The filing indicates a proposed sale of 963 shares of common stock with an aggregate market value of $57,341.84 by a person related to the issuer through Morgan Stanley Smith Barney LLC. The securities were acquired on February 13, 2026, as restricted stock from the Issuer.
Lost Money on Inspire Medical Systems, Inc. (INSP)? Urged to Join
Levi & Korsinsky LLP has filed a class action securities lawsuit against Inspire Medical Systems, Inc. (NYSE:INSP) on behalf of investors who suffered losses between August 6, 2024, and August 4, 2025. The lawsuit alleges that Inspire Medical Systems made false statements and concealed critical issues regarding the disastrous launch of its Inspire V product, including poor demand, surplus inventory, and failures in training, IT systems, and reimbursement processes. Shareholders are urged to join the class action before January 5, 2026, to recover their losses.
Inspire Medical Systems, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Inspire Medical Systems (NYSE:INSP) saw an 18% stock price increase after beating Q2 revenue expectations by 3.1% and reporting a statutory profit of US$0.01. Despite this, analysts forecast a revenue reduction for 2026 and expect the company to incur losses, yet they raised the average price target by 17%. The company's revenue is predicted to decline while the broader industry is set to grow, suggesting Inspire Medical Systems will lag its peers.
UBS Adjusts Inspire Medical Systems Price Target to $40 From $39, Maintains Sell Rating
UBS has adjusted its price target for Inspire Medical Systems (INSP) to $40 from $39, while maintaining a Sell rating on the stock. The article mentions that Inspire Medical Systems currently has an average hold rating and a mean price target of $57.21. Full details are available with a premium subscription.
Inspire Medical Systems (INSP) Stock Jumps As Profit Returns Through Revenue Slip
Inspire Medical Systems (INSP) saw its stock jump 23% after reporting Q2 earnings, despite a 7.6% revenue slip due to coding and reimbursement issues. The company returned to a small quarterly profit of US$0.01 per share and achieved positive operating cash flow, along with announcing a restructuring plan (Project Horizon) to create US$30m in annual investment capacity. Bulls focus on the company's platform strength and self-funding growth, while bears highlight ongoing reimbursement disruptions and execution risks.
Inspire Medical Systems, Inc. Stock 12‑Month Price Target Raised to $60.33, Implies 16% Upside
Analysts have raised the average 12-month price target for Inspire Medical Systems, Inc. (INSP) stock from $51.43 to $60.33, indicating a potential 16% upside from its Aug. 3 closing price. This new target is based on estimates from 15 analysts, with individual forecasts ranging from $39 to $85 per share. Despite the increased price target, the consensus rating from 18 analysts remains "Hold," with 5 Buys, 11 Holds, and 2 Sells.
Inspire Medical Systems (NYSE: INSP) files Form 4 on RSU tax withholding
Inspire Medical Systems' Chief People Officer, Melissa Mann, filed a Form 4 detailing tax-withholding dispositions related to the vesting of Restricted Stock Units (RSUs). A total of 652 shares were withheld across two transactions on July 31, 2025, and July 31, 2026, to cover tax obligations. These were not open-market sales but rather standard tax處理 for RSU vesting.
Why Are Inspire Medical Systems (INSP) Shares Soaring Today
Inspire Medical Systems (INSP) shares surged by 18.3% after the company reported better-than-expected quarterly results, raised its full-year guidance, and announced a new corporate restructuring initiative called Project Horizon. Oppenheimer upgraded the stock to Outperform with an $85 price target. This positive news follows a previous period of significant decline for the stock due to lowered forecasts in 2025.
Inspire Medical Systems (INSP) Stock May Be A Bargain On Raised 2026 Guidance
Inspire Medical Systems (INSP) has experienced a significant stock price decline over the past three years, yet current valuations suggest the shares are either fairly valued or undervalued. A Discounted Cash Flow (DCF) model estimates an intrinsic value of $56 per share, indicating the stock trades at a modest 7% discount. Furthermore, its P/E ratio of 11.5x is below the industry average and a tailored fair P/E of 15.2x, pointing to an undervalued stock based on earnings.
INSPIRE MEDICAL SYSTEMS INC : JP MORGAN RAISES TARGET PRICE TO $60 FROM $54
JP Morgan has increased its target price for Inspire Medical Systems Inc (INSP.N) to $60 from $54. This update reflects the analyst's revised outlook on the company's valuation. The article is a brief news alert from Reuters regarding this financial adjustment.
Inspire Medical Systems Q2 2026 Earnings Call Transcript
Inspire Medical Systems (INSP) reported its Q2 2026 earnings, exceeding expectations despite a 7.6% revenue decrease to $200.6 million due to coding and reimbursement challenges. The company increased its full-year 2026 outlook for revenue, adjusted operating margin, and adjusted EPS, citing improved profitability and reimbursement trends. Inspire also announced "Project Horizon," a strategic growth plan to create $30 million in annualized investment capacity to accelerate revenue growth by optimizing organizational structure and supply chain, with primary focus on enhancing patient access, education, and prior-authorization support.
Inspire Medical Systems earnings beat by $0.38, revenue topped estimates
Inspire Medical Systems (NYSE: INSP) exceeded analyst expectations for its second-quarter earnings, reporting an EPS of $0.14 against an estimated $-0.24. The company also surpassed revenue estimates, bringing in $200.6 million compared to the consensus of $194.67 million. Looking ahead, Inspire Medical Systems projects FY 2026 revenue to be between $835.00 million and $875.00 million.
Earnings call transcript: Inspire Medical beats Q2 2026 estimates, shares jump
Inspire Medical Systems (INSP) surpassed Q2 2026 revenue and adjusted EPS estimates, leading to a significant jump in shares despite a 7.6% year-over-year revenue decline due to coding and reimbursement issues. The company introduced "Project Horizon," a strategic growth plan to optimize operations and invest $30 million annually into patient access and education initiatives, with a revised full-year revenue outlook of $835 million to $875 million. Management expressed optimism about improving prior authorization trends and positive proposed changes to Medicare facility reimbursement rates for 2027.
Inspire Medical Systems Q2 Adjusted Earnings, Revenue Fall; Raises 2026 Revenue Guidance
Inspire Medical Systems reported a decrease in Q2 adjusted earnings and revenue but exceeded FactSet estimates. The company posted adjusted EPS of $0.14 against an estimated $-0.24, and Q2 revenue of $200.6 million against an estimated $194.7 million. Despite the fall in adjusted earnings and revenue, the company has raised its 2026 revenue guidance.
Inspire Medical Systems, Inc. Announces Second Quarter 2026 Financial Results, Raised 2026 Guidance, and Strategic Growth Plan
Inspire Medical Systems announced its second-quarter 2026 financial results, reporting revenue of $200.6 million and diluted EPS of $0.01. The company raised its full-year 2026 revenue guidance to $835 million to $875 million and introduced "Project Horizon," a strategic growth plan designed to generate $30 million in annualized growth investment capacity for redeployment into new initiatives.
Inspire Medical Q2 revenue falls to $200.6 million as guidance raised
Inspire Medical (INSP) reported second-quarter 2026 revenue of $200.6 million, a 7.6% decrease year-over-year, with net earnings of $0.3 million. Despite the revenue fall, the company raised its full-year 2026 revenue outlook to $835 million to $875 million and announced "Project Horizon," a strategic growth plan expected to generate $30 million in annualized growth investment capacity. The report also detailed insider trading activity and hedge fund movements related to INSP stock.
What To Expect From Inspire Medical Systems’s (INSP) Q2 Earnings
Inspire Medical Systems (INSP) is scheduled to announce its Q2 earnings this Monday after the bell. Analysts expect a 10.3% year-on-year revenue decline, despite the company's history of exceeding expectations. Its peers, Bausch + Lomb and Baxter, recently reported stronger-than-anticipated Q2 results.
Vanguard Portfolio Management (INSP) discloses 2.13M-share, 7.37% stake in Inspire
Vanguard Portfolio Management LLC has disclosed an amended 7.37% beneficial ownership stake in Inspire Medical Systems Inc., totaling 2,126,116 shares. The filing indicates Vanguard has sole voting power over 37,155 shares and sole dispositive power over all 2,126,116 shares, held across various Vanguard funds and managed accounts. No single person other than Vanguard holds more than 5% interest through these holdings.
UBS Downgrades Inspire Medical Systems(INSP.US) to Sell Rating, Cuts Target Price to $39
UBS has downgraded Inspire Medical Systems (INSP.US) to a Sell rating, reducing its target price to $39. This revised outlook suggests a negative sentiment from UBS regarding the company's future stock performance.
BlackRock (INSP) reports 4.16M Inspire Medical shares, 14.4% ownership stake
BlackRock, Inc. has filed an amended ownership report, revealing that its reporting business units beneficially own 4,163,016 shares of Inspire Medical Systems, Inc. common stock, which accounts for 14.4% of the outstanding class as of June 30, 2026. BlackRock holds sole voting power over 4,116,712 shares and sole dispositive power over all 4,163,016 shares. The filing also notes that iShares Core S&P Small-Cap ETF has an interest exceeding five percent in Inspire Medical Systems' common stock.
INSPIRE MEDICAL SYSTEMS INC : UBS ASSUMES COVERAGE WITH SELL VS NEUTRAL RATING; TARGET PRICE $39 VS $67
UBS has initiated coverage on Inspire Medical Systems Inc. (INSP.N) with a "Sell" rating, a downgrade from a "Neutral" stance. The investment bank has also significantly lowered its target price for the company's stock to $39, down from the previous target of $67.
INSPIRE MEDICAL SYSTEMS INC : UBS ASSUMES COVERAGE WITH SELL VS NEUTRAL RATING; TARGET PRICE $39 VS $67
UBS has initiated coverage on Inspire Medical Systems Inc. (INSP.N) with a "Sell" rating, a downgrade from a previous "Neutral" stance. The new target price for the stock is set at $39, significantly lower than the prior $67. This information was reported by Reuters.
UBS Downgrades Inspire Medical Systems to Sell From Neutral, Cuts Price Target to $39 From $67
UBS has downgraded Inspire Medical Systems (NASDAQ: INSP) from Neutral to Sell and significantly cut its price target from $67 to $39. This decision reflects a more cautious outlook on the medical technology company, which specializes in solutions for obstructive sleep apnea. The downgrade suggests that UBS analysts anticipate potential headwinds for Inspire Medical Systems in the near future.
INSP|Inspire Medical Systems Inc|Price:50.920|Chg%:+1.730
This article provides a comprehensive stock analysis of Inspire Medical Systems Inc (INSP), highlighting its relatively healthy fundamentals, high growth potential, and fair valuation. Despite high institutional ownership, technical indicators do not fully support the current trend, suggesting range-bound trading. The company specializes in minimally invasive solutions for obstructive sleep apnea, with its Inspire therapy approved in multiple regions.
Inspire Medical Systems, Inc. Announces Appointment of Seasoned Medical Device Executive Michael H. Carrel to its Board of Directors
Inspire Medical Systems, Inc. (NYSE: INSP) has announced the appointment of Michael H. Carrel, a veteran medical device executive, to its Board of Directors, effective July 20. Carrel, who has led AtriCure, Inc. as CEO since 2012, brings extensive experience in developing and commercializing minimally invasive therapies, and previously served as Chairman of Axonics, Inc. His appointment is expected to provide valuable guidance as Inspire continues to advance its therapy for obstructive sleep apnea (OSA) and expand patient access.
Inspire Medical Systems (NYSE: INSP) awards 5,631 RSUs to board member Carrel
Inspire Medical Systems (NYSE: INSP) has granted 5,631 restricted stock units (RSUs) to board member Michael H. Carrel. These RSUs vest in three equal annual installments, contingent upon his continued service on the board. Following this award, Carrel directly holds 5,631 RSUs.
